Zynerba Pharmaceuticals Announces New FAB-C Phase 2

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
52
Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 - - Presentation Today at the 16 th NFXF International Fragile X Conference -

DEVON, Pa., July 12, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ: ZYNE ), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is reporting today new open label clinical data in an oral presentation at the 16th NFXF (National Fragile X Foundation) International Fragile X Conference. The presentation will take place during the Industry Updates session at 4:30 PM EDT today in the Regency Ballroom of the Hyatt Regency, Cincinnati Ohio. A copy of the presentation and poster are available on the Zynerba corporate website at http://zynerba.com/publications/ .

In a podium presentation entitled, “Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS),” Liza A. Squires, M.D., Zynerba’s Chief Medical Officer, will present new 12- and 38-week data describing significant and sustained improvements in behavioral symptoms with continued use of ZYN002 in children and adolescents with FXS. The presentation includes data through 38 weeks of treatment with ZYN002 in the open label Phase 2 FAB-C (Treatment of F ragile X Syndrome A nxiety and B ehavioral C hallenges with CBD) trial.

The data demonstrate that treatment with ZYN002 improved core behavioral symptoms of Fragile X syndrome with statistical significance versus baseline across multiple measures of efficacy at week 12, and these improvements were sustained through 38 weeks of treatment.  ZYN002 was well tolerated; no serious adverse events were reported, and no clinically meaningful trends in vital signs, ECG, or clinical safety laboratories, including liver function tests (LFTs), were observed.

“These data are consistent and compelling, and suggest that ZYN002 may have a clinically meaningful and durable effect on the most common observable behaviors associated with childhood and adolescent Fragile X syndrome,” said Honey Heussler, FRACP, DM, Associate Professor, University of Queensland and Medical Director Child Development, Children’s Health Queensland, and lead investigator in the FAB-C study. “The goal of an ideal therapeutic intervention is to reduce the severity and impact of these core symptoms, and thus improve the child’s ability to engage with the world around them, including with their parents, caregivers, teachers and peers. It is very encouraging that measurable improvements in behaviors were observed in this study across a variety of instruments, whether validated for use by caregivers or physicians. I am delighted by these data; however, we need the results from the recently initiated CONNECT-FX study for confirmation. I look forward to participating in the continued development of ZYN002 for these children.”

Study design

Twenty patients (3:1 males) aged 6 to 17 years of age (median = 9) with Fragile X were enrolled in the open label FAB-C study. All patients had genetic confirmation of the full mutation of the FMR1 gene. ZYN002 was added to other medications being administered. The first six weeks were designed to titrate dosing in patients. Dosing was initiated at 50 mg daily and could be increased to 250 mg daily. Weeks seven through 12 was a maintenance period where patients were treated at the dose established at week six. Two patients, who were siblings, discontinued during the initial 12-week period; one discontinued due to worsening eczema (not considered treatment related) and the other discontinued for administrative reasons. At the completion of week 12, 13 patients elected to enter into the extension study for up to 24 months. To date, 12 patients remain in the study and have now exceeded 12 months of therapy with ZYN002.

Week 12 Efficacy

As previously disclosed, the 12-week FAB-C study achieved its primary endpoint, which was reduction in the Anxiety, Depression, and Mood Scale (ADAMS) total score from baseline to week 12 (n=18; 45.8% reduction; p<0.0001). Four of the five subscales of ADAMS also showed statistically significant reductions versus baseline.

 Scale: ADAMS Baseline (n=20) Week 12 (n=18) Week 12 % Improvement Group Mean P-value vs Baseline
 ADAMS Total Score 33.4 18.1 45.8 <   0.0001
  General Anxiety 10.0 4.6 54.0 < 0.0001
  Social Avoidance 10.2 4.8 52.9 0.0002
  Compulsive Behavior 2.8 1.4 50.0 0.0262
        Manic/Hyperactive Behavior 9.4 6.1 35.1 0.0003
  Depressed Mood 2.8 2.0 28.6 0.1417

As previously disclosed, ZYN002 achieved statistically significant reductions in all six subscales of a secondary endpoint, the Aberrant Behavior Checklist – Community: FXS Specific (ABC-C FXS ).

 Scale: ABC-C FXS Baseline (n=20) Week 12 (n=18) Week 12 % Improvement Group Mean P-value vs Baseline
 Stereotypy 7.9 3.2 59.5 0.0006
 Social Avoidance 5.1 2.3 54.9 0.0005
 Socially Unresponsive/Lethargic 8.7 4.1 52.9 0.0034
 Inappropriate Speech 6.1 3.5 42.6 0.0018
 Irritability 18.2 10.6 41.8 0.0096
 Hyperactivity 14.5 9.8 32.4 0.0237

Zynerba is also releasing today the results of additional secondary efficacy endpoints that were evaluated in the first 12 weeks of the FAB-C trial, which the Company believes further reinforces the results from the ADAMS and ABC-C FXS , regardless of whether assessments were completed by a caregiver or physician. These measurements include:

 Scale Baseline (n=20) Week 12 (n=18) Week 12 % Improvement Group Mean P-value vs Baseline
 CGI-I  n/a 2.5* n/a n/a
 PARS-R 15.6 10.6 32.1 0.0006
 PedsQL: Total 57.3 67.7 18.2 0.0100
 VAS: Hyperactivity/Impulsivity 6.2 3.6 41.9  0.0002
 VAS: Tantrum/Mood Lability 5.0 3.2 36.0 0.0023
 VAS: Anxiety 6.2 3.8 38.7 0.0005
 Vineland Adaptive Behavior 48.3 48.9 1.2 0.0472

* N=17 at week 12

The Clinical Global Impression Scale – Improvement (CGI-I) is a clinician-rated single-item 7-point scale that measures change in a patient’s condition following the start of a treatment. Ratings of one through three represent improvement; a rating of four represents no change; ratings of five through seven represent worsening of symptoms.

Long Term Efficacy: 12 and 38 Week

The following data show the improvement in various efficacy measures for the patients who completed 12 weeks, enrolled in the extension trial, and have completed 38 weeks of treatment.

Anxiety, Depression, and Mood Scale (ADAMS)   

 Scale: ADAMS Group Mean Percent Improvement from Baseline
Week 12 (n=12) P-value vs Baseline Week 38 (n=12) P-value vs Baseline
 ADAMS Total Score 48.6 0.0001 59.2 <0.0001
  General Anxiety 55.1 <0.0001 58.2 <0.0001
  Social Avoidance 52.5 0.0013 61.6 0.0007
  Compulsive Behavior 50.0 0.0295 59.4 0.0247
  Manic/Hyperactive Behavior 34.1 0.0012 53.4 0.0002
  Depressed Mood 43.8 0.0831 62.5 0.0372

A photo accompanying this chart is available at:  http://www.globenewswire.com/NewsRoom/Attachm...a583c98190

Aberrant Behavior Checklist – Community: FXS Specific (ABC-C FXS )  

 Scale: ABC-C FXS Group Mean Percent Improvement from Baseline
Week 12 (n=12) P-value vs Baseline Week 38 (n=9) P-value vs Baseline
 Stereotypy 60.8 0.0048 73.2 0.0019
 Social Avoidance 57.9 0.0040 75.4 0.0013
 Socially Unresponsive/Lethargic 65.7 0.0024 83.3 0.0016
 Inappropriate Speech 56.5 0.0002 66.1 <0.0001
 Irritability 51.1 0.0012 63.7 0.0003
 Hyperactivity 36.7 0.0119 48.2 0.0012

A photo accompanying this chart is available at: http://www.globenewswire.com/NewsRoom/Attachm...053cbd4a29  

Safety Summary

ZYN002 was well tolerated, and the safety profile was consistent with previously reported clinical data, with no serious adverse events (SAEs) reported. Forty-three treatment-emergent adverse events (TEAEs) have been reported through week 38, all of which were mild or moderate. Most were unrelated to treatment with ZYN002. The most common TEAEs were gastroenteritis (14%) and upper respiratory tract infections (12%); all were considered unrelated and resolved during the study period. One patient, who has continued in the trial, developed moderate application rash, which resolved. No THC was detected in the plasma. No clinically meaningful trends in vital signs, ECG, or clinical safety laboratories including liver function tests (LFTs) were observed.

The Company plans to seek publication of these data and will provide future updates on the ongoing FAB-C study.

About Fragile X syndrome (FXS)

Fragile X syndrome is a rare genetic developmental disability that is the leading known cause of both inherited intellectual disability and autism spectrum disorder, affecting 1 in 3,600 to 4,000 males and 1 in 4,000 to 6,000 females. It is the most common inherited intellectual disability in males and a significant cause of intellectual disability in females. It is caused by a mutation in the Fragile X Mental Retardation gene (FMR1) located on the X chromosome and leads to dysregulation of the endocannabinoid pathway including the reduction in endogenous cannabinoids (2-AG and anandamide). The disorder negatively affects synaptic function, plasticity and neuronal connections, and results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. In the US, there are about 71,000 patients suffering with FXS.

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and refractory epilepsies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company’s ability to obtain additional funding to support its clinical development programs; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; clinical results for the Company’s product candidates may not be replicated or continue to occur in additional trials and may not otherwise support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration and foreign regulatory agencies may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company’s ability to obtain and maintain regulatory approval for its product candidates, and the labeling under any such approval; the Company’s reliance on third parties to assist in conducting pre-clinical and clinical trials for its product candidates; delays, interruptions or failures in the manufacture and supply of the Company’s product candidates the Company’s ability to commercialize its product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates; and the Company’s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates. This list is not exhaustive and these and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at  www.sec.gov . Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Contact

Will Roberts, VP Investor Relations and Corporate Communications Zynerba Pharmaceuticals 484.581.7489 robertsw@zynerba.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 61

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 10

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 20

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 24

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
Haemonetics Opens Europe for VASCADE MVP XL Device

Updated Category News Views 31

A larger collagen plug is hardly cocktail-party material, yet it can matter a great deal when it sits inside a procedure workflow hospitals are trying to speed up. Haemonetics has received CE Mark certification under the EU Medical Device Regulation for VASCADE MVP XL, its larger-bore venous vascular closure system, and first commercial European procedures were completed...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 85

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Photocure Opens a New Access Route for Hexvix Patients

Updated Category News Views 31

Forty-plus markets just moved from “not available” toward a workable route for individual bladder cancer patients, and that is the real substance of Photocure’s new arrangement with Clinigen. This is not a sweeping product launch, nor is it an approval announcement dressed up in confetti. It is a Named Patient Program, which matters because the regulatory plumbing...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 68

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 0

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading

Top 5 Most Recently Viewed Articles

Carrier Global Under Fire: An Investor's Investigation

Updated Category News Views 63

Sometimes the heat in the boardroom can match the heat of a summer's day. Enter Carrier Global Corporation (NYSE: CARR), where a group of folks who should've had their numbers kept tidy started playing with fire. Now there's an invite to a showdown from Schall, Brown & Schwartz LLP. They've thrown down the gauntlet to dig into whether Carrier’s statements could put them...

Continue Reading
Wise Group Faces Class Action Over Misleading Statements

Updated Category News Views 15

Wise Group plc: Legal Storm Brewing on the Horizon Looks like Wise Group's NASDAQ journey might be hitting some turbulence. Shareholders who picked up shares of the NASDAQ ticker WSE between May 11 and July 23, 2026, are getting a nudge to join a class action lawsuit that's gaining steam. Nothing sends a chill down a stockholder’s spine quite like the term "materially...

Continue Reading
FTI Consulting Enhances AI Capabilities with New Leadership

Updated Category News Views 151

FTI Consulting Announces New Senior Director for AI Innovation Global business advisory firm FTI Consulting, Inc. (NYSE: FCN), has recently appointed Brian Knudson as Senior Managing Director in the Data & Technology Transformation practice within the Corporate Finance & Restructuring segment. This strategic hire showcases FTI's commitment to enhancing its capabilities in...

Continue Reading
Viasat Launches Government Services via ViaSat-3 F1 Satellite

Updated Category News Views 156

Viasat Launches Government Services via ViaSat-3 F1 Satellite Viasat is now providing crucial satellite services to the U.S. Marine Corps using the ViaSat-3 network. This launch marks a significant stride towards enhancing connectivity for government operations. Connecting Military Operations The Marine Wing Communications Squadron 38 (MWCS-38) and the 3rd Marine Littoral...

Continue Reading
Automatic Trash Cans: A Game-Changer for Households

Updated Category News Views 87

Tired of Wrestling with Trash Cans? You'd think in this high-tech era, someone would've cracked the code on trash day drudgery. Well folks, the TRASH HAULER might just be the answer. Created by an inventive mind from Manhattan, Kansas, this gizmo is out to revolutionize the way we handle our garbage—by doing the heavy lifting for us on pickup day. The Idea Behind TRASH...

Continue Reading